A longitudinal biomarker panel centered on plasma GFAP can distinguish harmful mechanisms from protective adaptation. The decisive experiment is to measure plasma GFAP before and after endothelial exosome profiling in stratified models.
No AI visual card yet
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
flowchart TD
A["Pericyte Stress PDGFR-beta Signaling Loss"]
B["Astrocyte Reactivity A1 Pro-Inflammatory Polarization"]
C["GFAP Upregulation Intermediate Filament Assembly"]
D["GFAP Release Plasma Biomarker Elevation"]
E["BBB Disruption Endothelial-Pericyte Uncoupling"]
F["SASP and Complement S100B and C1q Secretion"]
G["Neuronal Vulnerability Synapse Loss"]
A --> E
B --> C
C --> D
E --> B
E --> F
F --> G
D -.->|"biomarker of"| G
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style C fill:#7b1fa2,stroke:#ce93d8,color:#ce93d8
style D fill:#1b5e20,stroke:#81c784,color:#81c784
style G fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
7 citations5 with PMID5 mediumValidation: 0%6 supporting / 1 opposing
✓For(6)
5
No opposing evidence
(1)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
The UNC5C T835M mutation associated with Alzheimer's disease leads to neurodegeneration involving oxidative st…MEDIUM▼
The UNC5C T835M mutation associated with Alzheimer's disease leads to neurodegeneration involving oxidative stress and hippocampal atrophy in aged mice.
causal direction requires longitudinal perturbation
skeptic_round
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
IF plasma GFAP separates causal BBB injury from compensation, THEN GFAP will rise by >=15% only in participants with concurrent pericyte-stress extracellular vesicle signatures over 12 months.
pendingconf: 0.57
Expected outcome: GFAP annual increase >=15% is enriched in the high pericyte-stress EV group with odds ratio >=2.0.
Falsified by: GFAP rise is independent of pericyte-stress EV status or odds ratio <1.2.
Method: Longitudinal plasma biomarker cohort measuring GFAP and endothelial/pericyte extracellular vesicles over 12 months.
IF GFAP reflects harmful BBB-linked astrocyte activation, THEN BBB-stabilizing treatment in a pericyte-stress mouse model will lower plasma GFAP by >=20% within 8 weeks.
pendingconf: 0.52
Expected outcome: BBB stabilization reduces plasma GFAP >=20% and improves tracer leakage >=25% versus vehicle.
Falsified by: GFAP reduction is <5% despite improved tracer leakage, or GFAP falls without BBB improvement.
Method: Pericyte-stress or BBB-leak mouse model treated with BBB-stabilizing intervention; plasma GFAP and tracer leakage at 8 weeks.